A new publication from Celon Pharma S.A. laboratories!

Our new publication on experimental oncology has just appeared! The article entitled “Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphoma.” by Daria Zdzalik and co-workers was published in Journal of Cancer Research and Clinical Oncology and is freely available via PubMed/PMC.

We are presenting the results of our research at the ECC in Amsterdam

Celon Pharma S.A. will participate in The European Cancer Congress 2013, which will be held in Amsterdam, the Netherlands. We will be presenting two posters at a session which is taking place on 29 September 2013: “Epithelial-mesenchymal transition confers resistance to FGFR inhibitors in gastric cancer cell line” and “Design and development of active andRead more »

Merger of Celon Services and Celon Pharma

The Company’s Management Board announces that the process aiming at the merger of Celon Services and Celon Pharma began on 1 July 2012, pursuant to Article 492 par. 1 point 1 of the Code of Commercial Companies. Download the Merger plan Celon Pharma Sp. z o. o 05-092 Kiełpin Ul. Ogrodowa 2A NIP 118 16Read more »

Celon Pharma received the Polish Agency for Enterprise Development (PARP)’s award for the most innovative project

On 15 May this year, the official award ceremony in a competition organised by the Polish Agency for Enterprise Development in cooperation with the Polish Society for Supporting Entrepreneurship took place. The goal of the competition was to honour modern and innovative business solutions. Celon Pharma received the main award in the “Innovative pharmaceutical andRead more »

Celon Pharma on MKNOL

Celon Pharma is going to present on  VIII Multidisciplinary Conference on Drug Science (MKNOL) in Hotel Ossa & Spa near Rawa Mazowiecka. We’ve prepared two lectures: CPL-200-075, a novel potent renal sodium-glucose cotransporter 2 (SGLT2) inhibitor and Design and development of CPL-407-22 – novel, potent and selective JAK2 protein kinase inhibitor.

We have launched a Computer-assisted Drug Design Lab

We have launched a Computer-assisted Drug Design Department. The unit’s task will be to support, in terms of bioinformatics and chemoinformatics, the process of designing active substances: developing methodology, conducting and analysing virtual screening, analysing the binding of active particles with proteins, estimating and assessing ADMET parameters, creating QSAR models. The Department has a wideRead more »